A.L.I. acquisition reaches completion
McKesson announced July 8 the final acquisition of A.L.I. Technologies. The A.L.I. line of PACS products, now known as Horizon Medical Imaging, complements McKesson's Horizon Clinicals suite. Together, the two technologies will provide integrated access
McKesson announced July 8 the final acquisition of A.L.I. Technologies. The A.L.I. line of PACS products, now known as Horizon Medical Imaging, complements McKesson's Horizon Clinicals suite. Together, the two technologies will provide integrated access to the complete patient record. The goal behind the acquisition is to consolidate the technologies needed to automate and streamline workflow along every step of the diagnostic process from the time a test is ordered until the image is interpreted and the results are distributed to the referring physician, according to the company. The acquisition boosts McKesson's customer base to more than 500 installations. A.L.I. will be known as the McKesson Medical Imaging Group. Its employees will remain in the Vancouver, BC, location.
Meta-Analysis Shows No Difference Between bpMRI and mpMRI in Ruling Out csPCa
March 6th 2025In an 18-study meta-analysis involving over 4,600 patients, researchers found that bpMRI and mpMRI had equivalent pooled negative predictive value (NPV) of 92 percent for clinically significant prostate cancer (csPCa).
Is MRI Contrast Enhancement Necessary for Long-Term Monitoring of Diffuse Glioma?
March 4th 2025In a comparison of contrast-enhanced T1-weighted (CET1w) MRI (and T2-weighted MRI/FLAIR imaging, researchers found that only three out of 82 cases of glioma progression were solely detected with CET1w MRI.
